Neuromyelitis optica and Susac-Syndrome

Summary

The exclusion of relevant differential diagnoses is crucial in the establishment of the diagnosis of multiple sclerosis. Neuromyelitis optica and Susac-Syndrome are rare but because of different therapeutic approaches and prognoses important differential diagnoses of multiple sclerosis. While the former is increasingly considered to be rather an independent disease than a variant of multiple sclerosis, the diagnosis of the latter is quite often completely missed. This review summarizes the most important aspects of both disorders with a focus on features facilitating the discrimination from multiple sclerosis.

Keywords

Multiple sclerosis - neuromyelitis optica - Susac-Syndrome - differential diagnosis

• Literatur

• 1 Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372 9648 1502-17.
• 2 McDonald WI. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50 (01) 121-7.
• 3 Polman CH. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58 (06) 840-6.
• 4 Wingerchuk DM. et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 06 (09) 805-15.
• 5 Weinshenker BG. et al. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 2006; 05 (02) 110-1.
• 6 Lucchinetti C. et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002; 125 (07) 1450-1.
• 7 Lennon VA. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364 9451 2106-12.
• 8 Lennon VA. et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202 (04) 473-7.
• 9 Paul F. et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007; 04 (04) e133.
• 10 Jarius S. et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68 (13) 1076-7.
• 11 Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 06 (07) 383-92.
• 12 Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation 2008; 05: 22.
• 13 Wingerchuk DM. et al. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999; 53 (05) 1107-14.
• 14 Poppe AY. et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005; 11 (05) 617-21.
• 15 Magaña SM. et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 72 (08) 712-7.
• 16 Wingerchuk DM. et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66 (10) 1485-9.
• 17 Pittock SJ. et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63 (03) 390-6.
• 18 Sellner J. et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17 (08) 1019-32.
• 19 de Seze J. et al. Is Devic’s neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003; 09 (05) 521-5.
• 20 McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 1990; 113 (05) 1269-89.
• 21 Waters P. et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008; 65 (07) 913-9.
• 22 Jarius S. et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 2010; 291 (1–2) 52-6.
• 23 Kalluri SR. et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 2010; 67 (10) 1201-8.
• 24 Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003; 60 (05) 848-53.
• 25 Watanabe S. et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007; 13 (01) 128-32.
• 26 Cree BAC. et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64 (07) 1270-2.
• 27 Trebst C. [Diagnosis and treatment of neuromyelitis optica: Consensus recommendations of the Neuromyelitis Optica Study Group.]. Nervenarzt. 2010 Dez 22 www.ncbi.nlm.nih.gov/pubmed/21174070
• 28 Bot JCJ. et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004; 62 (02) 226-33.
• 29 Weinshenker BG. et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59 (03) 566-9.
• 30 Jarius S. et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatr 2008; 79 (10) 1134-6.
• 31 Susac JO, Hardman JM, Selhorst JB. Microangiopathy of the brain and retina. Neurology 1979; 29 (03) 313-6.
• 32 Eluvathingal TJMuttikkal, Vattoth S, Keluth VNChavan. Susac syndrome in a young child. Pediatr Radiol 2007; 37 (07) 710-3.
• 33 McLeod DS. et al. Retinal and optic nerve head pathology in Susac’s Syndrome. Ophthalmology. 2010 Okt 2 www.ncbi.nlm.nih.gov/pubmed/20920828
• 34 O’Halloran HS. et al. Microangiopathy of the brain, retina, and cochlea (Susac syndrome). A report of five cases and a review of the literature. Ophthalmology 1998; 105 (06) 1038-44.
• 35 Petty GW. et al. Retinocochleocerebral vasculopathy. Medicine (Baltimore) 1998; 77 (01) 12-40.
• 36 Heiskala H. et al. Microangiopathy with encephalopathy, hearing loss and retinal arteriolar occlusions: two new cases. J Neurol Sci 1988; 86 (2–3) 239-50.
• 37 Barker R. et al. Microangiopathy of the brain and retina with hearing loss in a 50 year old woman: extending the spectrum of Susac’s syndrome. J Neurol Neurosurg Psychiatr 1999; 66 (05) 641-3.
• 38 Ballard E, Butzer JF, Donders J. Susac’s syndrome: neuropsychological characteristics in a young man. Neurology 1996; 47 (01) 266-8.
• 39 Bogousslavsky J. et al. Encephalopathy, deafness and blindness in young women: a distinct retinocochleocerebral arteriolopathy?. J Neurol Neurosurg Psychiatry 1989; 52 (01) 43-6.
• 40 MacFadyen DJ, Schneider RJ, Chisholm IA. A syndrome of brain, inner ear and retinal microangiopathy. Can J Neurol Sci 1987; 14 (03) 315-8.
• 41 Monteiro ML. et al. A microangiopathic syndrome of encephalopathy, hearing loss, and retinal arteriolar occlusions. Neurology 1985; 35 (08) 1113-21.
• 42 Papeix C. et al. [Susac’s syndrome: improvement with combined cyclophosphamide and intravenous immunoglobulin therapy]. Rev Neurol (Paris) 2000; 156 (8–9) 783-5.
• 43 Susac JO. Susac’s syndrome: the triad of microangiopathy of the brain and retina with hearing loss in young women. Neurology 1994; 44 (04) 591-3.
• 44 Tashima K. et al. Susac’s syndrome: beneficial effects of corticosteroid therapy in a Japanese case. Intern Med 2001; 40 (02) 135-9.
• 45 Magro C. Susac’s syndrome: an autoimmune endotheliopathy. Abstract presented at 1st Susac’s Syndrome Symposium, held at Ohio State University, Columbus. 2005
• 46 Susac JO, Egan RA, Rennebohm RM, Lubow M. Susac’s syndrome: 1975–2005 microangiopathy/ autoimmune endotheliopathy. J Neurol Sci 2007; 257 (1–2) 270-2.
• 47 Waldman J, Knight D. Antiendothelial cell antibodies in Susac’s syndrome. Abstract presented at the 1st Susac’s Syndrome Symposium, held at Ohio State University, Columbus. 2005
• 48 Jarius S. et al. Anti-endothelial serum antibodies in a patient with Susac’s syndrome. J Neurol Sci 2009; 285 (1–2) 259-61.
• 49 Aubart-Cohen F. et al. Long-term outcome in Susac syndrome. Medicine (Baltimore) 2007; 86 (02) 93-102.
• 50 Petty GW. et al. Recurrence of Susac syndrome (retinocochleocerebral vasculopathy) after remission of 18 years. Mayo Clin Proc 2001; 76 (09) 958-60.
• 51 Dörr J. et al. Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome. Nat Rev Neurol 2009; 05 (12) 683-8.
• 52 Susac JO. et al. MRI findings in Susac’s syndrome. Neurology 2003; 61 (12) 1783-7.
• 53 White ML, Zhang Y, Smoker WR. Evolution of lesions in Susac syndrome at serial MR imaging with diffusion-weighted imaging and apparent diffusion coefficient values. AJNR Am J Neuroradiol 2004; 25 (05) 706-13.
• 54 Kleffner I. et al. Diffusion tensor imaging demonstrates fiber impairment in Susac syndrome. Neurology 2008; 70 (19 Pt 2) 1867-9.
• 55 Egan RA, Hills WL, Susac JO. Gass plaques and fluorescein leakage in Susac Syndrome. J Neurol Sci 2010; 299 (1–2) 97-100.
• 56 Hilgert E, Harrèus U, Kramer MF, Matthias C. [Susac’s syndrome. A rare microangiopathy of cochlea, retina, and brain]. HNO 2006; 54 (04) 303-6.
• 57 Papo T. et al. Susac syndrome. Medicine (Baltimore) 1998; 77 (01) 3-11.
• 58 Pawate S, Agarwal A, Moses H, Sriram S. The spectrum of Susac’s syndrome. Neurol Sci 2009; 30 (01) 59-64.
• 59 Mallam B, Damato EM, Scolding NJ, Bailey C. Serial retinal fluorescein angiography and immune therapy in Susac’s syndrome. J Neurol Sci 2009; 285 (1–2) 230-4.
• 60 Rennebohm RM, Egan RA, Susac JO. Treatment of Susac’s Syndrome. Curr Treat Options Neurol 2008; 10 (01) 67-74.
• 61 Fox RJ. et al. Treatment of Susac syndrome with gamma globulin and corticosteroids. J Neurol Sci 2006; 251 (1–2) 17-22.
• 62 Gean-Marton AD. et al. Abnormal corpus callosum: a sensitive and specific indicator of multiple sclerosis. Radiology 1991; 180 (01) 215-21.
• 63 Paty DW. et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38 (02) 180-5.